1. Antimoniato de meglumine perilesional en leishmaniasis cutánea con falla terapéutica sistémica: serie de casos
- Author
-
Aleida Verduguez-Orellana, Marisol Córdova Rojas, Ernesto Rojas Cabrera, and Miguel Guzmán-Rivero
- Subjects
Gynecology ,Local pain ,medicine.medical_specialty ,business.industry ,lcsh:R ,lcsh:Medicine ,Leishmaniasis ,General Medicine ,medicine.disease ,Lesion ,falla terapéutica ,tratamiento perilesional ,Cutaneous leishmaniasis ,leishmaniasis cutánea ,efectos adversos ,medicine ,Therapeutic failure ,In patient ,medicine.symptom ,business - Abstract
espanolEn Bolivia, los medicamentos utilizados para el tratamiento de la leishmaniasis cutanea son los antimoniales, de aplicacion sistemica en dosis/kg peso, los cuales provocan efectos adversos por la aplicacion en largos periodos y grandes volumenes. La aplicacion perilesional de antimonio tiene similar eficacia terapeutica que la sistemica. Sin embargo, no se cuenta con informacion documentada respecto a la eficacia del tratamiento perilesional en pacientes con falla terapeutica, posterior al tratamiento sistemico. El objetivo de esta serie de casos fue evaluar el tratamiento perilesional con glucantime®, en pacientes con leishmaniasis cutanea y falla terapeutica, posterior a un primer ciclo de tratamiento sistemico con antimoniales. El estudio se realizo con once pacientes con leishmaniasis cutanea con falla terapeutica, posterior a la administracion de un primer ciclo de tratamiento sistemico con glucantime® procedentes de la zona tropical de Bolivia. Se considero como falla terapeutica la persistencia de la lesion y presencia de parasitos obtenidos de los bordes de la lesion. La intervencion perilesional consistio en la aplicacion dia por medio de glucantime® en cinco sesiones. La inoculacion se realizo sobre el borde de la lesion y la dosificacion del medicamento se calculo multiplicando el area de la lesion por el factor 0.008. Todos los pacientes presentaron dolor local durante el momento de inoculacion del medicamento, asi como tambien presentaron un ligero agrandamiento del area de la lesion despues de la primera aplicacion del medicamento En las siguientes inoculaciones se observo la reduccion progresiva del area de la lesion hasta su completa cicatrizacion. EnglishIn Bolivia, the drugs used for the treatment of cutaneous leishmaniasis are the antimonials by systemic application in doses / kg/weight, which cause adverse effects due to the applications in long periods and large volumes. The perilesional application of antimony has similar therapeutic efficacy than the systemic one. However, there is no documented information regarding the efficacy of perilesional treatment in patients with therapeutic failure after systemic treatment. The aim of this series of cases was to evaluate the perilesional treatment with Glucantime®, in patients with cutaneous leishmaniasis and therapeutic failure, after a first cycle of systemic treatment with antimonials. The study was conducted with eleven patients with cutaneous leishmaniasis and therapeutic failure, after the administration of a first cycle of systemic treatment with Glucantime®. from the tropical zone of Bolivia. The persistence of the lesion and the presence of parasites at the edge of the lesion were considered as therapeutic failure. The perilesional intervention consisted in the application past one day of glucantime® in five sessions. The inoculation was performed on the edge of the lesion and the dosage of the medication was calculated by multiplying the area of the lesion by the factor 0.008. All the cases presented local pain during the time of inoculation of the drug, as well as a slight enlargement of the area of the lesion after the first inoculation of the drug. In the following inoculations the progressive reduction of the area of the lesion was observed until its complete healing.
- Published
- 2020